Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin

Biotech giant Regeneron Pharmaceuticals (REGN) said Monday that sales of its linchpin Eylea drug in the final quarter of 2022 have been negatively impacted by a short-term shift to off-label use of rival drug Avastin. REGN stock plunged on the news. Citing preliminary data, Regeneron reported that…

#neweyedrug #switzerland #rocheholding #aflibercept #genentech #roche #regeneron